AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31477046 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester routine ultrasound
Number of subjects: 15
Study 28771918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) followed by Positive Psychology Intervention (PPI)
Number of subjects: 40
Study 28771918 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI) followed by Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study 28771918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and PPI
Number of subjects: 40
Study 28771918 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study 26103559 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with acid-etched surface combined with local application of melatonin gel at the osteotomy site
Number of subjects: 14
Study 26103559 — intervention group
Group type: COMPARATOR
Intervention: Implants with acid-etched surface
Number of subjects: 14
Study 25050592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone once daily (OOD)
Number of subjects: 68
Study 25050592 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone twice daily (OTD)
Number of subjects: 68
Study 23121995 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened routine information system (RIS)
Number of subjects: 0
Study 23121995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of investment to strengthen RIS
Number of subjects: 0
Study 19244043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (CRT)
Number of subjects: 53
Study 17312215 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated reminders (pager and e-mail)
Number of subjects: 2459
Study 17312215 — intervention group
Group type: COMPARATOR
Intervention: No reminders (Control group)
Number of subjects: 2459
Study 17312215 — intervention group
Group type: EXPERIMENTAL
Intervention: All staff receiving reminders after 2 months
Number of subjects: 2459
Study 17312215 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected compliance rate over 12 months
Number of subjects: 2459
Study 15343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Information only
Number of subjects: 88
Study 15343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping only
Number of subjects: 88
Study 15343550 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping plus information
Number of subjects: 88
Study 15343550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 15343550 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study 11640994 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 423
Study 11640994 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 423
Study 9840607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole (OFZ) 30 mg/kg
Number of subjects: 20
Study 9840607 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 20
Study 7977115 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occlusion in group 1 (mild to moderate stenosis)
Number of subjects: 50
Study 7977115 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occlusion in group 2 (severe stenosis)
Number of subjects: 50
Study 7977115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemia)
Number of subjects: 50
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with egg
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with wheat
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with milk
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (DBPCC) with soya
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additives (DBPCC) with tyramine and acetylsalicylic acid
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive tartrazine
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive sodium benzoate
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive sodium glutamate
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive sodium metabisulfite
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive acetylsalicylic acid
Number of subjects: 25
Study 2610332 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additive tyramine
Number of subjects: 25
Study 30920439 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling program (12 weeks)
Number of subjects: 115
Study 30920439 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification brochure (comparison group)
Number of subjects: 115
Study 30920439 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 115
Study 29180592 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise programme (12 sessions of circuit training over 6 weeks, supervised by a qualified exercise therapist)
Number of subjects: 86
Study 29180592 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 86
Study 26189234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (chewed for 1 min)
Number of subjects: 10
Study 26189234 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no intervention)
Number of subjects: 10
Study 23274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28
Study 23274503 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 21678032 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention to increase CRC screening
Number of subjects: 548
Study 21678032 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention with provider letter
Number of subjects: 548
Study 21678032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for self-report bias and missing data
Number of subjects: 548
Study 20002929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching with 20% carbamide peroxide (Opalescence PF 20%)
Number of subjects: 42
Study 20002929 — intervention group
Group type: COMPARATOR
Intervention: Nonbleaching group (stored in distilled water)
Number of subjects: 42
Study 20002929 — intervention group
Group type: EXPERIMENTAL
Intervention: Staining solutions (coffee and tea)
Number of subjects: 42
Study 16674606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1,200 mg/day
Number of subjects: 347
Study 16674606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1,800 mg/day
Number of subjects: 347
Study 16674606 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine 600 mg/day
Number of subjects: 347
Study 16674606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 15203576 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (IL) administered before meals
Number of subjects: 9
Study 15203576 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (IL) administered after meals
Number of subjects: 9
Study 11419234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) training
Number of subjects: 29
Study 11419234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT training)
Number of subjects: 29
Study 9260008 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle orifice cephalad (group I)
Number of subjects: 40
Study 9260008 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle orifice caudad (group II)
Number of subjects: 40
Study 8291367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (vanco+)
Number of subjects: 59
Study 8291367 — intervention group
Group type: COMPARATOR
Intervention: Control (vanco-)
Number of subjects: 59
Study 8291367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 3551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet (no cow milk and no egg from week 28 to delivery, with extra calcium and casein hydrolysate supplement)
Number of subjects: 212
Study 3551673 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 212
Study 3551673 — intervention group
Group type: COMPARATOR
Intervention: Normal food (including approximately 1/2 liter of milk/day and 3‐5 eggs/week)
Number of subjects: 212
Study 3551673 — intervention group
Group type: COMPARATOR
Intervention: Normal food
Number of subjects: 212
Study 31243691 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1162
Study 31243691 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 1162
Study 31243691 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued educational program
Number of subjects: 1162
Study 31243691 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary SOC
Number of subjects: 1162
Study 29153451 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel minimally invasive surgery combined with Kazakh exercise therapy
Number of subjects: 52
Study 29153451 — intervention group
Group type: COMPARATOR
Intervention: Continuous medial oblique surgical approach (Control)
Number of subjects: 52
Study 27643171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg/d
Number of subjects: 140
Study 27643171 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg/d
Number of subjects: 140
Study 25244465 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training intervention
Number of subjects: 1375
Study 25244465 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1375
Study 22331583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostracism condition
Number of subjects: 58
Study 22331583 — intervention group
Group type: COMPARATOR
Intervention: Included condition
Number of subjects: 58
Study 20664293 — intervention group
Group type: EXPERIMENTAL
Intervention: SNCA REP1 259 genotype (homozygous or heterozygous)
Number of subjects: 0
Study 20664293 — intervention group
Group type: EXPERIMENTAL
Intervention: SNCA REP1 263 genotype (homozygous or heterozygous)
Number of subjects: 0
Study 20664293 — intervention group
Group type: EXPERIMENTAL
Intervention: SNCA variations with pesticide exposure and smoking
Number of subjects: 0
Study 17573489 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 47
Study 17573489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17573489 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 47
Study 15757965 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks up to week 156
Number of subjects: 49
Study 12120881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH) 1500 mg daily for 10 days
Number of subjects: 40
Study 12120881 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 1000 mg daily for 10 days
Number of subjects: 40
Study 12120881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH)
Number of subjects: 40
Study 12120881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH) and Clarithromycin
Number of subjects: 40
Study 10440204 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal breast shield during radiotherapy
Number of subjects: 20
Study 10440204 — intervention group
Group type: COMPARATOR
Intervention: Standard breast radiotherapy without shield
Number of subjects: 20
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder (200 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder (400 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms) vs Budesonide (400 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms) vs Fluticasone propionate (200 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms) vs Fluticasone propionate (200 micrograms)
Number of subjects: 98
Study 7784789 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 98
Study 2125938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (AC) 500 mg with placebo
Number of subjects: 9
Study 2125938 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg and AC 500 mg
Number of subjects: 9
Study 2125938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NIC) 500 mg with placebo
Number of subjects: 9
Study 2125938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (AC) 500 mg
Number of subjects: 9
Study 2125938 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg
Number of subjects: 9
Study 7013865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, Vincristine, Daunorubicin or the same plus Cyclophosphamide for induction and reinductions
Number of subjects: 405
Study 7013865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Number of subjects: 405
Study 7013865 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal Methotrexate plus Ara‐C
Number of subjects: 405
Study 7013865 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Asparaginase consolidation
Number of subjects: 405
Study 7013865 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐Mercaptopurine and Methotrexate maintenance
Number of subjects: 405
Study 30665323 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 12 months
Number of subjects: 63
Study 30665323 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 months for 12 months
Number of subjects: 63
Study 27923565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound generator (SG) with counseling; assessed at three stages: initial, monitoring, and final (6 months after adaptation).
Number of subjects: 30
Study 27923565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound generator (SG) with hearing aid (HA) and counseling; assessed at three stages: initial, monitoring, and final (6 months after adaptation).
Number of subjects: 30
Study 25294665 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program of unilateral knee extensions for 12 weeks
Number of subjects: 11
Study 25294665 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulation of aponeurosis width increase
Number of subjects: 11
Study 24321801 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone 100 μg plus formoterol 6 μg as maintenance and reliever treatment
Number of subjects: 1714
Study 24321801 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 100 μg as reliever
Number of subjects: 1714
Study 21781653 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Tonafil®)
Number of subjects: 20
Study 21781653 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Viagra®)
Number of subjects: 20
Study 19657123 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg orally twice daily
Number of subjects: 3195
Study 19657123 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg subcutaneously every 12 hours
Number of subjects: 3195
Study 19657123 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3195
Study 19657123 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3195
Study 17526195 — intervention group
Group type: EXPERIMENTAL
Intervention: Biasten (budesonide plus salbutamol hemisuccinate)
Number of subjects: 46
Study 17526195 — intervention group
Group type: COMPARATOR
Intervention: Benacort (budesonide) plus Salben (salbutamol)
Number of subjects: 46
Study 17526195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Biasten and Benacort plus Salben)
Number of subjects: 46
Study 15888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 166
Study 15888150 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 166
Study 12784089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (CT; 200 U/day)
Number of subjects: 20
Study 12784089 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 20
Study 10532516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 0
Study 10532516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8682483 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐IFN alpha‐2a (5 million units, subcutaneously, thrice weekly)
Number of subjects: 18
Study 8682483 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐IFN alpha‐2b (5 million units, subcutaneously, thrice weekly)
Number of subjects: 18
Study 8682483 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 1830462 — intervention group
Group type: COMPARATOR
Intervention: Propofol induction and propofol-nitrous oxide maintenance (control)
Number of subjects: 92
Study 1830462 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and desflurane-nitrous oxide maintenance
Number of subjects: 92
Study 1830462 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-nitrous oxide
Number of subjects: 92
Study 1830462 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane alone for induction and maintenance
Number of subjects: 92
Study 1830462 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane in oxygen
Number of subjects: 92
Study 6122694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 18
Study 6122694 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (125 to 500 mg)
Number of subjects: 18
Study 6122694 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (500 mg)
Number of subjects: 18
Study 6122694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31213771 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride (1.5 mg/kg) infused intravenously (Group I)
Number of subjects: 115
Study 31213771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride (1.5 mg/kg) dripped into the tracheostomy tube (Group II)
Number of subjects: 115
Study 31213771 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% lidocaine aerosol (5 sprays, 22.5mg) sprayed into the tracheostomy incision (Group III)
Number of subjects: 115
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 104 PFU
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 105 PFU
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 106 PFU
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (adolescents)
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (children)
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 × 105 PFU
Number of subjects: 155
Study 28985239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (adolescents and children)
Number of subjects: 155
Study 27488181 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended depression treatment combining mobile and Internet technologies with face-to-face treatment
Number of subjects: 1200
Study 27488181 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 1200
Study 24380796 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHK intervention (n=48 fathers, n=72 children)
Number of subjects: 93
Study 24380796 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHK intervention
Number of subjects: 93
Study 24380796 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 93
Study 22595799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 372
Study 22595799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 19709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (four sessions)
Number of subjects: 50
Study 19709404 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 50
Study 17159193 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (4 mg intravenously every 6 months)
Number of subjects: 602
Study 17159193 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid (administered when LS or TH T score decreased to less than -2.0 or when a nontraumatic fracture occurred)
Number of subjects: 602
Study 15901026 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol-remifentanil
Number of subjects: 27
Study 15901026 — intervention group
Group type: COMPARATOR
Intervention: Inhaled anesthetic group (propofol-fentanyl-isoflurane)
Number of subjects: 27
Study 11953965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramid treatment strategy (initial NSAIDs, followed by chloroquine or sulfasalazine)
Number of subjects: 361
Study 11953965 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with chloroquine or sulfasalazine
Number of subjects: 361
Study 11953965 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with step-down prednisolone, methotrexate, and sulfasalazine (COBRA trial)
Number of subjects: 361
Study 11953965 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone (COBRA trial)
Number of subjects: 361